Clinical guideline: febrile seizures, diagnosis and treatment

Carlos Aguirre-Velázquez¹, Alma M. Huerta Hurtado², Hugo Ceja-Moreno³, Karina Salgado-Hernández⁴, Roberto San Román-Tovar⁵, Martha A. Ortiz-Villalpando⁶, Avril Molina-García⁷, Guadalupe Vargas-Ramírez⁸, Jaime López-Rivera⁹ and Rosana Huerta-Albarrán¹⁰

¹Escuela Nacional de Medicina TEC de Monterrey, Monterrey; ²Hospital de Pediatría Centro Médico Nacional De Occidente IMSS, Guadalajara, Jalisco; ³Hospital Civil Viejo Fray Antonio Alcalde, Guadalajara, Jalisco; ⁴Hospital Materno Infantil ISSEMYM, Toluca; ⁵Hospital General de Occidente Zoquipan, Zapopan, Jalisco; ⁶Centro de Rehabilitación Infantil e Inclusión Infantil de Occidente, CRIT, Guadalajara, Jalisco; ⁷Hospital Infantil de Especialidades de Chihauha, Chihauha; ⁸Hospital Pediátrico de León; León, Guanajuato; ⁹Hospital Universitario, Saltillo, Coahuila; ¹⁰Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico

Abstract

Febrile seizures (FeS) are the most common problem in pediatric neurological practice. They are convulsive episodes during the course of febrile illness in the absence of epilepsy, severe hydroelectrolytic imbalance or neuroinfection. Its diagnosis is clinical and classified as simple and complex. Febrile status epilepticus occurs in approximately 5% of cases. It is convenient to teach parents how to act in a seizure and clarify that a FeS is not epilepsy, it is a benign process that usually does not leave neurological sequelae, and in which mortality is zero. In this clinical guide, we indicate risk factors for recurrence, management instructions for the first FeS, as well as criteria for hospital admission and treatment for prolonged seizures.

Key words: Febrile Seizures. Diagnosis. Treatment.

1. What is a simple febrile seizure (SFeS)?

SFeS happen in children 3-5 months old¹-⁴. They are generalized tonic-clonic seizures accompanied by fever, without central nervous system (CNS) infection, metabolic disorder, or history of FeS⁵-⁸. Fever is considered as a rectal temperature greater than 38°C, axillary temperature greater than 37.5°C, or tympanic temperature greater than 38.2°C⁹. SFeS can occur before or after the fever becomes apparent, within 24 h, during the course of a febrile illness¹⁰-¹². SFeS affect 2-5 % of the pediatric population and they are reported to be more frequent in some ethnic Asian groups⁵,¹³,¹⁴. They are benign seizures, since they are induced convulsions and not related to epilepsy⁷,¹³.

2. What is a complex FeS (CFeS)?

A CFeS is a focal or generalized FeS lasting more than 15 min, recurrent (more than once in 24 h), and/or associated with postictal neurologic abnormalities, most commonly a postictal paralysis (Todd’s paralysis), or when the patient presents with previous neurological impairment¹⁵-¹⁷.

The child that presents with a prolonged FeS which was interrupted with anticonvulsant therapy (such as
diazepam (DZP)) before 15th min must also be classified within this group\textsuperscript{15,18}.

It is considered a febrile status epilepticus when a complex FeS lasts >30 min, or when there are shorter serial FeS without recovering consciousness during the interictal state\textsuperscript{6,10,15,16}.

### 3. When do you carry out a lumbar puncture in the first SFeS?

In children of any age that have their first FeS, it is important to discard an infection in the CNS (encephalitis/meningitis). Pay special attention when children are younger than 6 months, seizures last more than 15 min, there are more than two seizures within a 24-h time period when there are focal motor or non-motor seizures with altered alertness, and/or when the child presents the following clinical data:
- Sleepiness alternating with irritability or Glasgow scale below 15 points.
- Neck stiffness, Kernig’s sign, and Brudzinski’s sign.
- Vomiting, tense or bulging fontanelle, and papilledema.
- Presence of macular or petechial exanthem.
- Abnormal postures during the postictal state or if stupor remains for over an hour after a seizure\textsuperscript{6,19-21}.

The risk of bacterial meningitis in children that present with fever and seizures is about 3%, but in a CFeS it is 9%. Thus, lumbar puncture must be carried out in all children with CFeS and suspected CNS infection. In the case of CFeS without clinical signs of meningitis, they must be closely observed and checked after 2 h by a pediatrician to then decide again whether to carry out a lumbar puncture\textsuperscript{16} (Table 1).

### 4. How are SFeS or CFeS treated during the acute ictal phase?

Managing SFeS begins with training the parents for home management\textsuperscript{22} (Table 2). Informing the parents that their child will not die, that association with epilepsy is rare, and that the frequency of SFeS is reduced with age\textsuperscript{13,16,23,24}. Warning them that if the seizure lasts 5 min or more, they must call an ambulance, provide emergent initial therapy, or go to the emergency room. Various authors support that intervention during the acute phase is rarely required\textsuperscript{12,28}.

In the case of recurrent seizures, administer emergent initial therapy with the knowledge that the use of benzodiazepine may cause respiratory depression\textsuperscript{24}. Benzodiazepine intravenous (IV), intramuscular, oral, intranasal, or rectal can be used to abort the crisis but is not recommended for prophylactic treatment\textsuperscript{1,25} (Table 3).

In a systematic review about the use of AEDs for ongoing convulsive seizures, including epileptic status, they analyzed the efficacy and safety of using Midazolam (MDL), DZP, lorazepam (LZP), phenytoin (PHT), phenobarbital (PB), and paraldehyde, concluding that IV or rectal LZP is as effective or more effective than DZP\textsuperscript{26}. Oral MDL is more effective than rectal DZP, and the intranasal form is as effective as IV DZP. Oral or nasal MDL is the treatment of choice when there is no access to IV or for home management by the parents\textsuperscript{26-28} (Table 4).

---

**Table 1. Lumbar puncture in FeS and criteria for hospitalization**

<table>
<thead>
<tr>
<th>Data</th>
<th>Level of evidence</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar puncture must be obtained from children with FeS, younger than 12 months old, who have not completed their immunizations or have received previous antibiotic treatment</td>
<td>III</td>
<td>B</td>
</tr>
<tr>
<td>Lumbar puncture must be obtained from children of any age with FeS that present with altered alertness and/or meningeal symptoms</td>
<td>II</td>
<td>B</td>
</tr>
<tr>
<td>Children younger than 6 months with a simple FeS must be punctured unless an experienced pediatrician evaluates the patient and declines, but he must reevaluate the patient in 2 h</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td>All patients under 18 months with their first simple FeS must be admitted to the emergency room.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>Patients previously diagnosed with a recurrence of FeS do not require hospitalization</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>Hospitalization is not necessary in children older than 18 months that are clinically stable, without signs or symptoms that require diagnostic studies</td>
<td>I</td>
<td>A</td>
</tr>
</tbody>
</table>

FeS: febrile seizures
Table 2. Initial management of FeS at home

1. Remain calm. Loosen clothes, especially around the neck. Protect the child from injury during the FeS.
2. Do not introduce fingers or objects, or obstruct the mouth of the child. Do not force the mouth to open.
3. Once the seizure has passed, make sure the child is in an adequate lateral position for recovery, where the airway is not obstructed.
4. Observe the type of seizure or movement and its duration.
5. Explain that after the seizure the child will be asleep for up to 1 h.
6. In the case of recurrent FeS, administer an emergent initial therapy drug if there is a tonic-clonic seizure that lasts > 5 min.
7. Administer oral or nasal midazolam as first-line treatment. Rectal diazepam 0.5 mg/kg when midazolam is not available.
8. Seek medical attention if the seizure lasts > 5 min. Contact your pediatrician or other health professional.
9. The parents of children at high-risk for recurrence should receive the necessary training.

FeS: febrile seizures

Table 3. Emergent initial therapy for acute (ictal) management of FeS in children

<table>
<thead>
<tr>
<th>Antiepileptic</th>
<th>Administration route</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midazolam (15mg/3 ml vial)</td>
<td>Oral, Nasal, IV</td>
<td>Oral: 0.5 mg/kg, repeat in 10 min if necessary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intranasal: 0.2-0.5 mg/kg divided in each nostril, maximum 10 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intravenous: 0.2 mg/kg or 0.15 mg/kg by infusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intramuscular: 0.2 mg/kg or 5-10 mg, sole dose</td>
</tr>
<tr>
<td>Diazepam (10 mg/3 ml vial)</td>
<td>Rectal, IV</td>
<td>Rectal: 0.5 mg/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intravenous: 0.3-0.5 mg/kg, bolus speed of 5 mg/minute, repeat in 10 min if necessary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intramuscular: 0.01 mg/kg/min by infusion</td>
</tr>
<tr>
<td>Lorazepam (2 mg/3 ml vial)</td>
<td>Intravenous</td>
<td>Intravenous: 0.1 mg/kg (maximum 4 mg in children heavier than 40 kg)</td>
</tr>
</tbody>
</table>

IV: intravenous, IM: intramuscular. Oral Midazolam is more effective than rectal Diazepam, and the intranasal route is equally effective as IV diazepam (Level I evidence). Oral or nasal Midazolam is the treatment of choice when there is no access to IV or for home management by the parents (Level III evidence). FeS: Febrile seizures

Table 4. SF treatment in a hospital environment

1. Assess A, B, C
2. Open the airway, aspirate secretions, maintain adequate ventilation, and ensure perfusion.
3. Obtain venous access.
4. Monitor vital signs (heart rate, respiratory rate, arterial pressure, and pulse oximetry).
5. Administer oxygen, if necessary (SaO2 < 90%).
6. Administer an intravenous bolus of Diazepam at a dose of 0.5 mg/kg and a maximum infusion speed of 5 mg/min, discontinue when the seizure stops. The dose can be repeated, if necessary, after an interval of 10 min (consider that Diazepam takes about 10 m to reach an effective concentration in the brain, even using intravenous administration). Other benzodiazepines, like Lorazepam, are equally effective.
7. Monitor excess base and glucose in blood.
8. If the convulsion does not subside, ask for advice from a specialist to determine treatment.
9. The Febrile Status Epilepticus must be treated under the same treatment considerations as pediatric Afebrile Status Epilepticus.
10. The measures taken for fever reduction must begin after benzodiazepine administration, as long as it does not interfere with routine attention.
**Hospitalization criteria**

Independently of the length of the seizure, the patient must be assessed by medical history, documentation of SFeS history, epilepsy, immunizations, duration of the seizure, postictal phase, and any focal symptom. The American Academy of Pediatrics recommends that hospitalization is unnecessary for clinically stable patients older than 18 months, without signs or symptoms that require diagnostic studies. Parents are trained for home management (Table 1). Hospitalization recommended for children younger than 18 months, for observation and possible lumbar puncture. Patients previously diagnosed with recurrent FeS do not require hospitalization (Table 1).

5. Is long-term antiepileptic treatment required for FeS?

**Simple FeS, SFeS**

A systematic review that assesses the use of conservative and antipyretic measures concluded that there is no evidence that they have any usefulness in preventing SFeS recurrences. There is no evidence for the clinical usefulness of continuous or intermittent use of antiepileptic drugs (oral or rectal DZP, PB, diphenylhydantoin, or valproate) in SFeS. There is no evidence that continuous or intermittent treatment with antiepileptic drugs in SFeS can prevent the subsequent development of epilepsy.

**Complex FeS CFeS**

Long-term routine prophylaxis with antiepileptic drugs is not recommended since there is no clear information about their use in complex FeS. There is evidence that supports intermittent use of PB and antipyretics, clobazam, or rectal DZP, to prevent recurrence of complex FeS. However, the information does not clearly distinguish simple from complex seizures, and there may be bias due to the relative incidence of both types of seizures.

Regular use of antiepileptic drugs can be considered for patients with long or repetitive FeS despite the prophylactic use of DZP. Carbamazepine and PHT are not effective for preventing the recurrence of FeS and thus, should be avoided.

A prospective study, carried out in 2014, compared the efficacy of intermittent use of clobazam versus DZP to prevent recurrence of FeS (both simple and complex), as well as the adverse effects. The results showed that clobazam is safe, effective, requires a lower dose, and has fewer adverse effects than DZP, suggesting it as a good alternative for preventing recurrence of FeS. In addition, in 2017, another group demonstrated a significant difference in the prevention of recurrence after treatment with levetiracetam versus no treatment after 50 weeks (Table 5).

6. What paraclinical tests are necessary after the first FeS?

**Electroencephalogram**

Not indicated for the assessment of a neurologically healthy child with simple FeS. In a focal and/or prolonged convulsion, it is recommended to carry out an EEG and neurologic follow-up, due to the greater risk of developing epilepsy. A short, generalized convulsion that is repeated twice in 24 h is, by definition, a complex convulsion, but it is also not necessary to conduct an EEG unless the neurologic examination shows alterations.

The EEG does not allow prediction of which children are at greater risk to suffer new seizures. Epileptiform alterations in the EEG are relatively frequent in children with FeS. Few retrospective, cohort, case and control studies show a possible association between the epileptiform discharges in the EEG and a high risk of afebrile/epileptic seizures. The EEG has low sensitivity in children under 3 years of age, after an unprovoked convulsion.

**Laboratory tests**

They can be considered under certain clinical conditions but are not routinely carried out in a child after his first FeS with an evident source of infection. They will only identify the source of the child’s fever and are not necessary as part of the assessment of the seizure.

**Neuroimaging**

Highly recommended for patients with FeS that do not regain complete consciousness in hours, with prolonged Todd’s paralysis (post-critical), or with other...
7. What are the risk and recurrence factors for SFeS and CFeS?

Population risk of a FeS is 2.7-3.1%\textsuperscript{36}. The reported risk of recurrence after a first FeS is 27-32% of which 75% happen during the 1\textsuperscript{st} year after the first crisis\textsuperscript{18}. The risk of recurrence is similar between simple and complex FeS\textsuperscript{38}. The risk factors for FeS are enlisted in Table 7. The frequency of recurrence is 10% among patients with no risk factors; 25-50% in the presence of 1-2 risk factors; and 50-100% when there are three or more risk factors\textsuperscript{16}. The risk of developing epilepsy after a SFeS is 1.5-2.4% while for complex FeS it is estimated to be 4-15%\textsuperscript{39}, and in the case of focal FeS up to 29%\textsuperscript{40}.

8. When should cases of SFeS and CFeS be referred to the neuropediatrician?

FeS is a benign condition; they are not associated with neurodevelopmental damage nor do they cause secondary neurologic consequences\textsuperscript{6}. The only association found was between repeated FeS and a delay in language development; thus, new studies and longer-term follow-up will be required\textsuperscript{42}. Hippocampal malformations do not appear to be a consequence of FeS but can be a predisposing factor for the development of epilepsy.

---

Table 5. Long-term treatment for simple FeS and Complex SF

<table>
<thead>
<tr>
<th>Data</th>
<th>Level of Evidence</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermittent antipyretics, zinc, pyridoxin, or antiepileptic drugs are not useful for the prevention of recurrences of FeS</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>The continuous or intermittent use of antiepileptic drugs, such as DZP, PHT, PB, or VPA, is not useful</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>The continuous or intermittent use of antiepileptic drugs in FeS does not prevent the subsequent development of epilepsy</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>The regular use of antiepileptic drugs can be considered for patients with prolonged or repeated FeS despite the prophylactic use of diazepam</td>
<td>I, II</td>
<td>B</td>
</tr>
<tr>
<td>Levetiracetam could work as an antiepileptic drug for prevention of recurrence of FeS</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td>Clobazam is safe, effective and requires a lower dose than diazepam</td>
<td>II-II</td>
<td>C</td>
</tr>
<tr>
<td>Carbamazepine and phenytoin are not effective for the prevention of recurrence of FeS and should be avoided</td>
<td>II</td>
<td>B</td>
</tr>
<tr>
<td>Children with FeS should receive the complete recommended immunization program for their age</td>
<td>I</td>
<td>A</td>
</tr>
</tbody>
</table>

FeS: febrile seizures, DZP: diazepam, PHT: phenytoin, PB: phenobarbital

---

Table 6. Indications to carry out paraclinical tests in FeS

<table>
<thead>
<tr>
<th>Data</th>
<th>Evidence level</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conducting analytic tests routinely (CBC, blood glucose, electrolytes, calcium, and magnesium), are not useful for the management of children with FeS</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td>Routine cerebral imaging tests are not recommended for children with SFeS or CFeS. Neuroimaging is indicated for patients that do not regain complete consciousness in hours, with prolonged Todd’s paralysis (post-critical), or other focal alterations found in the neurologic exploration</td>
<td>II-III</td>
<td>C</td>
</tr>
<tr>
<td>Routine EEG is not recommended for children with SFeS</td>
<td>II</td>
<td>B</td>
</tr>
<tr>
<td>EEG in the case of focal FeS to discard seizures unleashed by fever</td>
<td>III</td>
<td>R-PPE</td>
</tr>
</tbody>
</table>

FeS: febrile seizure, SFeS: simple febrile seizure
of epilepsy. Providing the family with information about the illness and the risk of recurrence during the illness or in the future should be carried out by the pediatrician. However, if the clinical history shows >2 risk factors of seizure recurrence or the patient fulfills the requirements for complex FeS, we recommend he be referred to the neuropsychiatrician.

Table 7. FeS risk factors

<table>
<thead>
<tr>
<th>Recurrence after an initial FeS</th>
<th>Factors for developing epilepsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early onset (&lt;12 months)</td>
<td>Age during the first FeS: &lt;12 months or &gt;37 months</td>
</tr>
<tr>
<td>Epilepsy in first-grade family members</td>
<td></td>
</tr>
<tr>
<td>FeS in first-grade family members</td>
<td>Family history of epilepsy</td>
</tr>
<tr>
<td>Frequent febrile illnesses</td>
<td>Fever lasting &lt;1 h before the seizure</td>
</tr>
<tr>
<td>Temperature in the lower range of fever at the moment of the FeS</td>
<td></td>
</tr>
<tr>
<td>Fever lasting &lt;1 h before the seizure.</td>
<td>Low Apgar at 5 min</td>
</tr>
<tr>
<td></td>
<td>History of at least 1 CFeS</td>
</tr>
<tr>
<td></td>
<td>Febrile status epilepticus</td>
</tr>
<tr>
<td></td>
<td>Multiple seizures in 24 h</td>
</tr>
<tr>
<td></td>
<td>Focal seizures</td>
</tr>
<tr>
<td></td>
<td>Neurologic abnormalities (retarded development or CCP)</td>
</tr>
<tr>
<td></td>
<td>Focal epileptogenic discharges</td>
</tr>
</tbody>
</table>

CFeS: complex febrile seizure, FeS: febrile seizure

Conclusion

FeS is an age-dependent phenomenon, related to individual genetic predisposition and with a special vulnerability of the developing CNS to the effects of fever. The continued or intermittent prophylactic treatment with antiepileptic drugs does not reduce the risk of subsequent epilepsy and, although it is effective to reduce recurrences, its toxicity surpasses the few risks of FeS.

Informed and responsible parental counseling are the greatest contribution that the physician can make for the care of children with FeS.

References